10/561338 IAP9 Reg 4 PUT/PTO 15 DEC 2009

Attorney Docket No. 12504.548

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

United States Patent Application
United States National Stage of PCT/US04/19725

Applicant: ARIZONA BOARD OF REGENTS, a body

corporate of the State of Arizona, acting for

and on behalf of ARIZONA STATE

UNIVERSITY

Title: Pancratistatin Cyclic Phosphate Prodrugs and

Phenpanstatin Cyclic Phosphate Prodrugs

Serial No.: Unassigned

International Filing Date: 18 June 2004

U.S. Filing Date: December 15, 2005

Group Art Unit: Unassigned

Examiner: Unassigned

## INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir,

Attached to this Information Disclosure Statement is form PTO/SB/08A listing documents that may be relevant to the subject application. Applicant respectfully requests that these documents be considered by the examiner and an initialed copy of each page of the form be returned to the undersigned.

A copy of each listed document is enclosed. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

10/561338

IAPO Rec'd PCT/PTO 15 DEC 2009

INFORMATION DISCLOSURE STATEMENT

Docket No. 12504.548

Pancratistatin Cyclic Phosphate Prodrugs and Phenpanstatin Cyclic Phosphate Prodrugs

United States National Stage of PCT/US04/19725

Pursuant to 37 C.F.R. §§ 1.97 (g) and 1.97 (h), this disclosure statement should not be

construed as a representation that a search has been made or that the information cited in the

statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this disclosure complies with the requirements of 37 C.F.R. §§ 1.56.

1.97, and 1.98, and the Manual of Patent Examining Procedure § 609. If for some reason the

Examiner considers otherwise, the undersigned respectfully requests that she be called so that

any deficiencies can be remedied.

Dated: December 15, 2005

Respectfully submitted.

Susan Stone Rosenfield

FENNEMORE CRAIG

Reg. No. 36,287

3003 N. Central Avenue, Suite 2600

Phoenix, Arizona 85012-2913

Tel: (602) 916-5317

Fax (602) 916-5517

**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10** 

Express Mail Label No. EL 997 896 843 US

Date of Deposit: December 15, 2005

I hereby certify that this paper and all documents and any fee referred to herein are being deposited on the date indicated above with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, postage prepaid and addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

December 15, 2005 Date of Signature

## IAP9 Rec'd PCT/PTO 15 DEC 2009

## LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 (Use several sheets if necessary) Sheet 1 of 1 ATTY. DOCKET NO.: 12504.548 APPLICANT: George R. PETTIT et al. FILING DATE: December 15, 2005 TBA

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						<del>, .</del> .

FOREIGN PATENT DOCUMENTS								
			DATE	COUNTRY		SUBCLASS	TRANSLATION	
		DOCUMENT NUMBER			CLASS		YES	NO
	B1	WO 02/50023	27/06/2002	WIPO				
	B2					1		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
C1	International Search Report for PCT/US04/19725 dated January 11, 2005.				
C2	Written Opinion of the International Search Authority for PCT/US04/19725 dated January 11, 2005.				
C3	Pettit et al., "Antineoplastic Agents. 511. Direct Phosphorylation of Phenpanstatin and Pancratistatin", J. Nat. Prod., 67:322-327, (2004).				
C4					

EX	ΑN	1II	NER
----	----	-----	-----

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.